化浊解毒方对溃疡性结肠炎大鼠炎症免疫细胞因子的影响研究  

Effect of Huazhuo Jiedu decoction on inflammatory immune cytokines in rats with ulcerative colitis

作　　者：李博林[1] 杨倩[1] 何芳[1] 景璇[1] 才艳茹 赵丹阳 杜朋丽 LI Bolin;YANG Qian;HE Fang;JING Xuan;CAI Yanru;ZHAO Danyang;DU Pengli(Hebei Hospital of Traditional Chinese Medicine,Shijiazhuang 050011,Hebei,China)

机构地区：[1]河北省中医院,河北石家庄050011

出　　处：《现代中西医结合杂志》2019年第13期1373-1377,共5页Modern Journal of Integrated Traditional Chinese and Western Medicine

基　　金：河北省重点研发计划自筹项目(182777163);河北省中医药管理局科研计划项目(2018039)

摘　　要：目的研究化浊解毒方对溃疡性结肠炎大鼠血清白细胞介素-1β(IL-1β)及血浆P物质(SP)、血管活性肠肽(VIP)含量的影响,探讨该方治疗溃疡性结肠炎的作用机制。方法取60只雄性Wistar大鼠,随机选取15只大鼠作为正常组,其余45只大鼠采用TNBS/无水乙醇法诱导溃疡性结肠炎模型。然后将造模成功大鼠随机分为模型组、美沙拉嗪组及化浊解毒方组,每组14只。正常组常规饲养,模型组予0.9%NaCl溶液4 mL/(kg·d)灌胃,美沙拉嗪组予美沙拉嗪混悬液0.3 g/(kg·d)灌胃,化浊解毒方组予化浊解毒方混悬液20 g/(kg·d)灌胃,均1次/d,连续14 d。记录各组大鼠疾病活动指数(DAI)评分,观察结肠组织病理学变化,检测血清IL-1β及血浆VIP、SP含量。结果模型组大鼠DAI评分及血浆SP含量和血清IL-1β含量均明显高于正常组(P均<0.05),血浆VIP含量明显低于正常组(P均<0.05),结肠黏膜水肿、充血、溃疡明显。美沙拉嗪组、化浊解毒方组大鼠DAI评分及血浆SP含量和血清IL-1β含量均明显低于模型组(P均<0.05),血浆VIP含量均明显高于模型组(P均<0.05),结肠黏膜水肿、充血、溃疡明显减轻;且化浊解毒方组血浆VIP含量明显高于美沙拉嗪组(P<0.05),DAI评分及血清IL-1β含量均明显低于美沙拉嗪组(P均<0.05),结肠黏膜病理变化明显轻于美沙拉嗪组,但2组血浆SP含量比较差异无统计学意义(P>0.05)。结论化浊解毒方能够有效改善溃疡性结肠炎大鼠结肠病理损伤,其作用机制可能与平衡细胞因子,进而抑制炎症免疫损伤有关。Objective It is to study the effect of Huazhuo Jiedu decoction on serum interleukin-1β(IL-1β), plasma substance P(SP) and vasoactive enteropeptide(VIP) in rats with ulcerative colitis, and to explore the mechanism of this decoction in the treatment of ulcerative colitis. Methods 60 male Wistar rats were selected, in which 15 rats were randomly selected as the normal group. The method of TNBS/anhydrous ethanol was used to induce ulcerative colitis in the remaining 45 rats.Then the rats were randomly divided into model group, mesalazine group and Huazhuo Jiedu decoction group, with 14 rats in each group. The normal group was normally fed, the model group was given 0.9%NaCl solution 4 mL/(kg·d) by gavage, the mesalazine group was given 0.3 g/(kg·d) of mesalazine suspension by gavage, and the Huazhuo Jiedu decoction group was given 20 g/(kg·d) of Huazhuo Jiedu suspension by gavage, once a day for 14 days.The disease activity index(DAI) score of rats in each group was recorded, the histopathological changes of the colon were observed, and the contents of serum IL-1β and plasma VIP and SP were detected. Results DAI score, plasma SP content and serum IL-1β content of the model group were significantly higher than those of the normal group(P<0.05), plasma VIP content was significantly lower than that of the normal group(P<0.05), and colonic mucosa edema, hyperemia and ulcer were obvious.DAI score, plasma SP content and serum IL-1β content of rats in the mesalazine group and the Huazhuo Jiedu decoction group were significantly lower than those in the model group(P<0.05), plasma VIP content was significantly higher than that in the model group(P<0.05), and colonic mucosal edema, hyperemia and ulcer were significantly relieved.In addition, the plasma VIP level in the Huazhuo Jiedu decoction group was significantly higher while the DAI score and serum IL-1β level were significantly lower than those in the mesalazine group(P<0.05), and the pathological changes of colonic mucosa were more significant than those in the

关 键 词：溃疡性结肠炎 浊毒内蕴 化浊解毒 P物质 血管活性肠肽 白细胞介素-1β 

分 类 号：R574.62[医药卫生—消化系统]